Endothelial cells RNA silencing guide

Endothelial cells present unique biological barriers that can defeat conventional transfection or cost the vascular functions a study depends on:

Lipofection-induced junction disruption and barrier breakdown

Endothelial barrier function depends on VE-cadherin-mediated adherens junctions (homophilic VE-cadherin binding between adjacent cells, linked to actin cytoskeleton via β-catenin, α-catenin, p120-catenin) and tight junctions (claudin-5, occludin, ZO-1 scaffold). Cationic lipids disrupt these junctions through multiple mechanisms: (1) lipid insertion into plasma membrane alters membrane fluidity and lipid raft organization where junctional proteins localize, (2) calcium influx from membrane perturbation activates protein kinase C and Src kinases that phosphorylate VE-cadherin and β-catenin, triggering junction disassembly, (3) oxidative stress from lipoplexes activates RhoA/ROCK pathway causing actin-myosin contraction and cell retraction. Result: TEER often drops substantially within hours of lipofection, permeability to macromolecules (70 kDa dextran) rises, intercellular gaps form (visible by VE-cadherin immunofluorescence), and barrier function may not fully recover, depending on conditions. So a study that depends on an intact endothelial barrier can lose the baseline it reads against.

The viability cost of electroporation depends on the pulse programme

Primary endothelial cells are sensitive to electroporation, and what the pulse costs depends on the programme and the cargo. With a programme matched to the cell type, nucleofection of a messenger RNA into primary human umbilical vein endothelial cells at near confluence left the monolayer's morphology and confluency normal, with few dead cells, and delivered to most of the culture. A retracted monolayer, a spindle morphology or a diffuse VE-cadherin is therefore not what the pulse does by itself: each is read after the pulse, against a mock-electroporated well and against the monolayer's own TEER baseline. State the programme with the result, because it is the variable that moves the answer.

Extremely low transfection efficiency in primary endothelial cells

Primary human endothelial cells take up little by lipofection, and brain microvascular endothelial cells least of all. Primary endothelial cells have low pinocytic activity compared to immortalized cell lines and rapidly sequester lipoplexes into endosomal compartments for degradation. The cells that do take up cargo express it at widely different levels, creating mosaic populations that confound interpretation. For brain endothelial cells (critical for BBB studies), the low efficiency and the barrier disruption come together, so conventional transfection can cost the barrier a BBB study depends on.

Transfection-induced inflammatory activation

Endothelial cells are frontline sensors of vascular injury and infection. Cationic lipids and electroporation trigger inflammatory activation: upregulation of adhesion molecules (ICAM-1, VCAM-1, E-selectin), secretion of pro-inflammatory cytokines (IL-6, IL-8, MCP-1), increased leukocyte adhesion in co-culture assays, and activation of NFκB signaling (IκB degradation, p65 nuclear translocation). This inflammatory state confounds studies of endothelial activation, leukocyte trafficking, or cytokine-mediated signaling because transfection itself induces the phenotype being studied. For example, lipofection can itself induce ICAM-1, which leaves a study of TNF-α-induced ICAM-1 upregulation without a baseline to read the induction against.

Loss of angiogenic capacity post-transfection

Tube formation on basement membrane matrix is gold standard functional assay for angiogenic capacity. Lipofection-treated or electroporated HUVECs form fewer tubes after transfection: shorter tubes, increased fragmentation, and fewer branch points. This reflects multifactorial damage: cytoskeletal disruption (impaired filopodia extension and cell migration), altered integrin function (integrin αvβ3 and α5β1 required for basement membrane matrix adhesion and signaling), reduced responsiveness to VEGF and FGF2, and loss of tip cell vs. stalk cell coordination. For angiogenesis studies (VEGF pathway, Notch signaling, sprouting mechanisms), transfection can alter the process under investigation.

Tissue-specific endothelial cell sensitivity

Brain endothelial cells forming BBB are especially transfection-sensitive. These cells achieve higher junction tightness than HUVEC monolayers, express unique tight junction proteins (claudin-5 most abundant, essential for BBB), and have transporter systems of their own (P-glycoprotein/ABCB1, GLUT1, LAT1). Even at that low efficiency, lipofection often causes severe TEER loss, and barrier function often does not fully recover. Tumor endothelial cells isolated from tumors are fragile, and transfection can cost much of a preparation. Lymphatic endothelial cells show similar high sensitivity. This tissue specificity means a protocol optimized for HUVECs (most commonly used model) can fail in disease-relevant endothelial subtypes.

Method comparison

Transfection-free RNA silencing for endothelial cells

Key benefits

• Preserves BBB barrier integrity Brain endothelial BBB models form tighter barriers than HUVECs. Lipofection often causes severe BBB disruption (TEER may drop significantly, often does not fully recover). AUMsilence™ sdASO™ aims to maintain TEER stability during treatment, supporting BBB transport studies, tight junction knockdown experiments, and neurovascular unit modeling.
• Enables VEGF-induced permeability studies VEGF increases vascular permeability by triggering VE-cadherin phosphorylation and internalization (critical for edema, tumor leak, retinal disease). This measurement requires an intact baseline barrier. AUMsilence sdASO preserves baseline barrier, allowing measurement of VEGF-induced permeability increase to test genes controlling VEGF response (VEGFR2, VE-cadherin, S1PR1).
• Compatible with flow chamber and shear stress assays Endothelial cells respond to fluid flow (shear stress) by aligning, inducing KLF2, and expressing eNOS. Requires confluent monolayer adhered to substrate. AUMsilence sdASO is added to the medium with no transfection reagent and no electrical pulse, so neither of those two routes to detachment is taken; read adhesion and confluence against the untreated control before the flow run. Parallel-plate flow chambers, cone-plate viscometers and microfluidic devices are all usable. Study flow-responsive gene knockdown effects.
• Maintains junctional protein localization Immunofluorescence studies of junction proteins (VE-cadherin, claudin-5, ZO-1) require preserved spatial localization. Lipofection causes junctional protein mislocalization (diffuse cytoplasmic rather than concentrated at cell-cell borders). AUMsilence sdASO maintains normal junctional localization in non-targeting controls, enabling studying how specific knockdowns alter junction organization.
• Rapid timeline for angiogenesis studies No viral vector cloning (2-4 week production), no lipofection optimization (varies by batch and cell state). Add AUMsilence sdASO to confluent HUVECs, incubate 72h, perform tube formation assay. Test gene function in angiogenesis within 4-5 days total.
• Compatible with endothelial co-culture models Study endothelial-pericyte interactions, endothelial-astrocyte BBB models, endothelial-tumor cell co-cultures, and endothelial-leukocyte transmigration. AUMsilence sdASO can be added to established co-cultures.

Cell types and applications

• Primary human umbilical vein endothelial cells (HUVECs)
• Primary human brain microvascular endothelial cells (HBMECs, hCMEC/D3)
• Tumor-derived endothelial cells (mouse or human)
• Lymphatic endothelial cells (LECs)
• Endothelial cell lines (EA.hy926, HMEC-1)
• Blood-brain barrier models (permeable insert co-culture with astrocytes)
• Tube formation and sprouting assays
• TEER and permeability barrier assays
• Leukocyte adhesion and transmigration studies
• Flow chamber and shear stress experiments
• Angiogenesis mechanism studies (VEGF, Notch, angiopoietin pathways)
• Tumor angiogenesis and anti-angiogenic therapy resistance
• Vascular tone and eNOS regulation
• Inflammatory endothelial activation and atherosclerosis models

• Learn more about AUMsilence™ sdASO™

Alternative products

• AUMantagomir™ sdASO™ When to use: For microRNA inhibition in endothelial cells. Recommended for studying miR-126-3p (endothelial homeostasis, VEGF signaling, the abundant arm in endothelial cells), miR-221-3p and miR-222-3p (anti-angiogenic), and miR-92a-3p (flow-responsive, regulates KLF2 and atheroprotection).
• AUMlnc™ sdASO™ (long non-coding RNA targeting) When to use: For long non-coding RNA knockdown. MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) is highly expressed in endothelial cells and regulates angiogenesis, migration, and proliferation. Other endothelial lncRNAs: MANTIS (endothelial function), STEEL (angiogenesis).
• Custom ASO design service When to use: For novel endothelial targets, isoform-specific knockdown (e.g., VEGF165 vs. VEGF121), or multi-gene panels. AUM scientists design and validate 3-5 ASO candidates per target, optimized for human or mouse sequences.

Optimized protocols for primary endothelial cells (HUVECs, brain ECs, tumor ECs) and endothelial cell lines. Preserves barrier function, junctions, and angiogenic capacity. No transfection reagents required.

Quick start protocol (HUVECs)

1. 01Culture HUVECs on gelatin or fibronectin-coated plates in EGM-2 medium until confluent monolayer
2. 02Add AUMsilence™ sdASO™ directly to culture medium at 10 μM (no transfection reagent)
3. 03Incubate 48-72 hours at 37°C, 5% CO₂ (maintain cobblestone morphology)
4. 04Validate knockdown by qRT-PCR (48h after treatment) and Western blot or immunofluorescence (72h after treatment)
5. 05Verify barrier preserved: TEER measurement, VE-cadherin immunofluorescence (localization at junctions)
6. 06Perform functional assays: tube formation, permeability, leukocyte adhesion, migration/scratch wound

Cell-type-specific protocols

Human umbilical vein endothelial cells (HUVECs)

Primary vascular endothelial cells: gold standard model for angiogenesis and barrier function

1. 01

   Step 1: HUVEC culture and coating

   Obtain primary HUVECs from commercial sources (Lonza, ATCC, PromoCell) or isolate from fresh umbilical cords. Culture in EGM-2 medium (EBM-2 basal medium + growth factor bullet kit: VEGF, FGF2, EGF, IGF, hydrocortisone). Coat culture plates with gelatin (0.1%, 30 min at 37°C) or fibronectin (5 μg/cm², 1h at 37°C). Seed HUVECs at 2-3 × 10⁴ cells/cm² in 24-well plates (500 μL medium/well) or permeable inserts (for barrier assays). Use cells at passage 2-6 (early passage critical: HUVECs undergo endothelial-to-mesenchymal transition, EMT, at high passage, losing characteristic cobblestone morphology and junctional proteins). Culture to confluent monolayer (2-3 days); cells should display tight cobblestone morphology with no gaps.
   
   Materials: EGM-2 complete medium, gelatin or fibronectin, tissue culture plates
   
   Note: Confluence critical for barrier studies. Verify by phase-contrast microscopy: cobblestone morphology, tight cell-cell contacts, no gaps. Sub-confluent monolayers have inherently leaky barriers (not suitable for TEER or permeability studies). For angiogenesis assays, 80-90% confluence optimal (cells not contact-inhibited).
   
   Timing: Day -3 to Day 0
2. 02

   Step 2: AUMsilence sdASO treatment of confluent HUVECs

   At Day 0 (confluent monolayer established), add AUMsilence sdASO directly to EGM-2 medium at 10 μM final concentration. For 500 μL in 24-well, add 5 μL of 1 mM AUMsilence sdASO stock. Do NOT change medium during 48-72h incubation (medium change can disrupt monolayer). AUMsilence sdASOs bind proteins on the cell surface and are taken up by endocytosis, followed by intracellular trafficking; a small fraction escapes endosomes to reach the cytosol and nucleus where target engagement occurs via RNase H1. Cells remain confluent and maintain cobblestone morphology throughout treatment.
   
   Materials: AUMsilence sdASO (1 mM stock in nuclease-free water)
   
   Note: AUMsilence sdASO is added to EGM-2 with no media change, and the full serum and growth factor medium maintains cell health during the knockdown period. Serum proteins may reduce uptake.
   
   Timing: Day 0
3. 03

   Step 3: Incubation and barrier monitoring

   Incubate 48-72 hours. Monitor daily: (1) Morphology: brightfield microscopy to verify cobblestone morphology maintained, no cell retraction or gap formation. (2) Confluence: cells should remain confluent monolayer with tight junctions visible as dark lines between cells under phase contrast. (3) If performing TEER measurements (barrier assays), measure baseline TEER before ASO addition, then at 24h, 48h, 72h. TEER should remain stable against that baseline throughout treatment in the non-targeting control; a significant drop indicates barrier disruption.
   
   Materials: Inverted microscope, EVOM2 epithelial voltohmmeter (for TEER)
   
   Note: Critical validation: the non-targeting control shows whether the chemistry moved the barrier. If TEER drops significantly or cells retract in the non-targeting control ASO group, investigate potential issues (endotoxin contamination, medium pH shift, CO₂ fluctuation, or poor starting monolayer). Compare to untreated cells cultured identically.
   
   Timing: Days 0-3
4. 04

   Step 4: Validation of knockdown

   At 48h after treatment: qRT-PCR for mRNA. At 72h: protein validation by (1) Western blot for cytoplasmic or nuclear proteins (VEGFR2, NFκB, transcription factors), (2) Immunofluorescence: fix cells in monolayer (4% PFA, 15 min), permeabilize (0.1% Triton X-100, 10 min), stain for target protein and junctional markers (VE-cadherin, ZO-1, claudin-5). Image on confocal microscope; junction proteins should remain concentrated at cell-cell borders (continuous linear staining). (3) Flow cytometry: dissociate with gentle cell dissociation buffer or Cell Dissociation Buffer (do NOT use trypsin, as it damages surface proteins), stain for surface proteins (VEGFR2, ICAM-1, integrins). Include viability dye; viability preserved.
   
   Materials: RNA extraction, qPCR reagents, antibodies (VE-cadherin, ZO-1, claudin-5 for validation), gentle cell dissociation buffer
   
   Note: For junctional proteins (VE-cadherin, claudin-5, occludin): use immunofluorescence, which preserves spatial localization. Knockdown of junctional proteins will disrupt barrier (expected phenotype); measure TEER drop and increased permeability as functional validation. For signaling proteins (VEGFR2, Notch1, Tie2): Western blot or flow cytometry.
   
   Timing: Days 2-3
5. 05

   Step 5: Functional assays post-knockdown

   At 72h post-ASO, perform endothelial functional assays: (1) Tube formation assay: trypsinize HUVECs, seed 2 × 10⁴ cells/well on basement membrane matrix (growth factor-reduced, 10 mg/mL coating), incubate 6-18h, image tube networks. Quantify: total tube length, number of branch points, number of closed loops (WimTube software, ImageJ Angiogenesis Analyzer). (2) Barrier permeability: add FITC-dextran (70 kDa) to apical chamber of permeable insert, measure fluorescence in basolateral chamber after 1-4h. Calculate permeability coefficient. (3) Transendothelial electrical resistance (TEER): use EVOM2 meter with STX2 electrode, measure resistance (Ω), multiply by membrane area (cm²) to get Ω·cm², and compare it with the baseline measured before treatment. (4) Leukocyte adhesion: label THP-1 monocytes or primary neutrophils with calcein-AM, add to HUVEC monolayer (with or without TNF-α activation), incubate 30 min, wash, count adhered leukocytes by fluorescence microscopy. (5) Scratch wound migration: create scratch with pipette tip, image at 0h and 12-24h, measure gap closure (wound healing rate).
   
   Materials: Basement membrane matrix, FITC-dextran, permeable inserts, EVOM2 meter, leukocytes, calcein-AM
   
   Note: Expected results depend on target, and each assay is read against the non-targeting control. VEGFR2 knockdown leads to reduced tube formation, no baseline barrier change. VE-cadherin knockdown leads to increased permeability, reduced TEER and normal tube formation initially (junction-independent). ICAM-1 knockdown leads to reduced leukocyte adhesion after TNF-α stimulation, no baseline change. Claudin-5 knockdown (brain EC-specific) leads to increased small molecule permeability, TEER drop.
   
   Timing: Days 3-4

Human brain microvascular endothelial cells (HBMECs / blood-brain barrier model)

Endothelial cells forming the blood-brain barrier: high TEER, tight junctions

1. 01

   Step 1: Brain endothelial cell culture and BBB differentiation

   Obtain primary human brain microvascular endothelial cells (HBMECs, Cell Systems, ScienCell) or use immortalized hCMEC/D3 cell line (lower TEER but more accessible). Culture on collagen IV + fibronectin coating (50 μg/mL each, 2h at 37°C) which mimics basement membrane. For primary HBMECs: use complete brain EC medium with growth factors. Seed at high density (4-5 × 10⁴ cells/cm²) on permeable inserts (0.4 μm pore, polyester membrane) for barrier assays. Culture 5-7 days to establish tight barrier. Add astrocyte-conditioned medium or co-culture with astrocytes (bottom chamber of permeable insert) to enhance BBB phenotype: increases claudin-5 expression, reduces permeability, elevates TEER. Mature BBB model: TEER risen to a stable plateau above the monolayer's own starting value, with low permeability to small molecules (sucrose, mannitol).
   
   Materials: Collagen IV, fibronectin, brain EC medium, permeable inserts, astrocyte-conditioned medium
   
   Note: BBB differentiation requires astrocyte factors (TGF-β, GDNF, angiopoietin-1). Without astrocyte influence, brain ECs lose BBB characteristics (claudin-5 decreases, TEER drops). For drug transport studies, verify P-glycoprotein function (rhodamine 123 efflux assay) and GLUT1 expression (glucose transport).
   
   Timing: Day -7 to Day 0
2. 02

   Step 2: AUMsilence sdASO treatment of BBB monolayers

   At Day 7 (tight barrier established, confirmed against the monolayer's own baseline), add AUMsilence sdASO at 10 μM to apical (luminal) chamber. In brain ECs it is taken up by endocytosis. Incubate 48-72h. Monitor TEER daily: critical for BBB studies. In the non-targeting control, TEER should remain stable against that baseline. If targeting tight junction proteins (claudin-5, occludin, ZO-1), TEER will drop (expected functional consequence). If targeting transporters (ABCB1/P-gp, GLUT1), TEER should remain unchanged but transporter function altered.
   
   Materials: AUMsilence sdASO, EVOM2 meter
   
   Note: BBB brain ECs extremely sensitive to experimental perturbations. Minimize medium changes (causes shear stress and TEER fluctuations). If a medium change is necessary, perform it gently and simultaneously in apical and basolateral chambers to avoid hydrostatic pressure differences. Measure TEER before and after medium change; should return to baseline within 30 min.
   
   Timing: Day 0-3
3. 03

   Step 3: BBB functional validation

   At 72h post-ASO, measure BBB integrity and transport: (1) TEER measurement (see above). (2) Paracellular permeability: add sodium fluorescein (376 Da, paracellular marker) or FITC-dextran (70 kDa) to apical chamber, measure basolateral fluorescence over time. Calculate apparent permeability coefficient (P_app). Tight BBB: P_app <1 × 10⁻⁶ cm/s for sodium fluorescein. (3) Transporter function: for P-gp, add rhodamine 123 or [³H]-digoxin (P-gp substrates), measure apical-to-basolateral vs. basolateral-to-apical flux. P-gp-competent BBB shows efflux ratio (B→A / A→B) >5. Add P-gp inhibitor (verapamil, PSC833) to verify specificity. (4) Immunofluorescence: fix monolayers on permeable insert, stain for claudin-5, ZO-1, occludin, P-gp (ABCB1). Claudin-5 and ZO-1 should form continuous belts at cell-cell junctions (confocal microscopy, XZ cross-sections show apical localization). (5) Western blot: verify knockdown of target protein and assess off-target effects on other BBB proteins.
   
   Materials: Sodium fluorescein, FITC-dextran, rhodamine 123, P-gp inhibitors, tight junction antibodies
   
   Note: Expected BBB knockdown phenotypes, each read against the non-targeting control: Claudin-5 knockdown (most abundant BBB tight junction protein) leads to increased permeability to small molecules (<800 Da), TEER drop. Occludin knockdown leads to modest TEER reduction, claudin-5 localization unaffected (occludin not required for claudin assembly). ZO-1 knockdown leads to severe junction disruption, TEER drop, claudin-5 mislocalization (ZO-1 scaffolds claudins to actin). P-gp/ABCB1 knockdown leads to loss of efflux, increased brain accumulation of substrates (model drug delivery across BBB). GLUT1/SLC2A1 knockdown leads to reduced glucose transport, impaired brain glucose supply.
   
   Timing: Day 3-4

Tumor-derived endothelial cells

Endothelial cells isolated from tumors: abnormal structure, unique markers

1. 01

   Step 1: Tumor endothelial cell isolation and culture

   Isolate endothelial cells from tumor tissue (mouse tumor models or human tumor specimens). Digest tumor tissue with collagenase + dispase (30-60 min, 37°C), create single-cell suspension, enrich endothelial cells by magnetic bead selection (CD31+/CD45- to exclude leukocytes, or CD31+/CD146+). Alternatively, use FACS sorting (CD31+CD45-CD146+). Seed on fibronectin-coated plates in EGM-2 medium. Tumor ECs initially heterogeneous and fragile; purify by 1-2 passages, verify endothelial identity by CD31, VE-cadherin, vWF expression. Tumor ECs display characteristic abnormal morphology: irregular shape, less organized monolayers than HUVECs, often retain some tumor-educated phenotype (high VEGFR2, neuropilin-1, low pericyte coverage markers [NG2, PDGFRβ]).
   
   Materials: Collagenase, dispase, CD31/CD146 MicroBeads, EGM-2 medium
   
   Note: Tumor ECs lose some tumor-specific characteristics upon culture (normalization). For authentic tumor EC studies, use early passage (P1-P3) and compare to normal ECs from same tissue/organ. Tumor EC fragility: handle gently, expect lower viability than HUVECs.
   
   Timing: Isolation + 1-2 weeks expansion
2. 02

   Step 2: AUMsilence sdASO treatment of tumor ECs

   Seed tumor ECs at confluence, add AUMsilence sdASO at 10 μM. In tumor ECs it is taken up by endocytosis. Target tumor EC-specific genes: neuropilin-1 (NRP1, enhances VEGF165 signaling), angiopoietin-2 (ANGPT2, vessel destabilization), Tie2/TEK receptor, integrin αvβ3 (angiogenic integrin), or DLL4/Notch (tip-stalk cell specification). Incubate 48-72h.
   
   Materials: AUMsilence sdASO
   
   Note: Tumor ECs often more angiogenic than normal ECs (higher basal tube formation, migration). Knockdown of pro-angiogenic genes should reduce this aberrant activity.
   
   Timing: Day 0-3
3. 03

   Step 3: Functional validation in tumor EC context

   Perform tumor-relevant functional assays: (1) Tube formation: tumor ECs form more extensive tube networks than HUVECs; quantify to assess anti-angiogenic knockdown effects. (2) Sprouting assay: embed tumor EC spheroids in fibrin or collagen gel, measure sprout length and number. (3) Permeability: tumor vessels are leaky; measure if knockdown further increases or normalizes permeability. (4) Co-culture with tumor cells: seed tumor ECs in permeable insert, tumor cells in bottom chamber, measure endothelial migration or tube formation in response to tumor-secreted factors (VEGF, FGF2). Test if knockdown blocks tumor-induced angiogenesis. (5) Pericyte recruitment: co-culture tumor ECs with pericytes, measure pericyte coverage (NG2, PDGFRβ co-staining by IF). Angiopoietin-1 or PDGFB knockdown reduces pericyte recruitment.
   
   Materials: Basement membrane matrix, fibrin gel, tumor cell lines, pericytes
   
   Note: Tumor EC phenotypes: NRP1 knockdown leads to reduced VEGF165 responsiveness, impaired sprouting (NRP1 is VEGF165 co-receptor). ANGPT2 knockdown leads to vessel stabilization, increased pericyte coverage (ANGPT2 antagonizes ANGPT1-Tie2 stabilization). Integrin αvβ3 knockdown leads to reduced adhesion to matrix proteins (vitronectin, fibronectin), impaired migration. DLL4 knockdown leads to excessive tip cell formation (loss of lateral inhibition), hypersprouting but dysfunctional vessels.
   
   Timing: Day 3-5

Endothelial cell lines (EA.hy926, HMEC-1, hCMEC/D3)

Immortalized cell lines for high-throughput screening and mechanistic studies

1. 01

   Step 1: Cell line culture

   EA.hy926 (HUVEC-derived hybrid): culture in DMEM + 10% FBS + HAT supplement. HMEC-1 (dermal microvascular EC): culture in MCDB131 + 10% FBS + EGF + hydrocortisone. hCMEC/D3 (brain EC line): culture on collagen + fibronectin in EBM-2 + growth factors. Cell lines grow faster than primary cells, reach confluence in 2-3 days. Use at 80-90% confluence for angiogenesis assays, 100% confluence for barrier assays.
   
   Materials: Cell line-specific media
   
   Note: Cell lines have advantages (unlimited passage, no donor variability, stable phenotype) and disadvantages (genetic alterations from immortalization, may not recapitulate all primary cell biology). Use for initial screening, validate key findings in primary cells.
   
   Timing: Maintain stock cultures
2. 02

   Step 2: AUMsilence sdASO treatment

   Add AUMsilence sdASO at 10 μM. Incubate 48-72h.
   
   Materials: AUMsilence sdASO
   
   Note: Cell lines useful for high-throughput target screening, multi-gene combinatorial knockdown, and time-course experiments (unlimited cells). Lower cost than primary cells.
   
   Timing: Day 0-3
3. 03

   Step 3: Validation and screening assays

   Use cell lines for: (1) siRNA/ASO sequence optimization (test 5-10 sequences per target, identify most effective), (2) Pathway mapping (knock down multiple pathway components in parallel: VEGFR2, PLCγ, ERK, AKT to map signaling), (3) High-content screening (96-well tube formation, migration, proliferation assays), (4) Temporal dynamics (time-course sampling at 6h, 12h, 24h, 48h, 72h post-ASO to track mRNA and protein decay kinetics). After identifying hits in cell lines, validate in primary HUVECs or disease-relevant primary ECs.
   
   Materials: Standard validation reagents, multi-well plates for screening
   
   Note: Example workflow: screen 20 candidate genes in EA.hy926 (tube formation assay, 96-well), identify top 5 hits, validate in HUVECs, further validate in brain ECs or tumor ECs for disease context.
   
   Timing: Days 2-5

Essential controls for endothelial cell experiments

• Untreated endothelial cells: Baseline for morphology, TEER, permeability, tube formation, and junctional protein localization
  Culture identically but without ASO. Important baseline control for comparing effects of AUMsilence sdASO treatment on barrier function or angiogenic capacity.
• Non-targeting control ASO: Control for non-specific ASO effects on endothelial function
  Use AUM non-targeting control at 10 μM. Measure TEER, permeability, VE-cadherin localization, tube formation; should be similar to untreated cells. If non-targeting ASO significantly alters any parameter, investigate potential off-target effects or endotoxin contamination.
• Positive control for barrier disruption: Validate that barrier assays detect endothelial dysfunction
  Thrombin (1 U/mL, 10 min) causes rapid VE-cadherin junction disassembly, TEER drop (50-80%), increased permeability. Serves as positive control for barrier breakdown. VEGF (50 ng/mL, 30 min) increases permeability (vascular leak). TNF-α (10 ng/mL, 4-6h) upregulates ICAM-1, VCAM-1 (inflammatory activation control).
• Junction integrity validation: Ensure baseline junctions intact before and during ASO treatment
  Immunofluorescence for VE-cadherin and ZO-1 at Day 0 (before ASO) and Day 3 (after ASO, in non-targeting control). Both should show continuous linear staining at cell-cell borders. Discontinuous or diffuse staining indicates junction disruption (experimental problem).
• Viability and confluence assessment: Ensure ASO treatment does not cause cytotoxicity or monolayer gaps
  At 24h, 48h, 72h after treatment: (1) Viability: trypan blue or viability/cytotoxicity dual staining, (2) Morphology: cobblestone morphology maintained, (3) Confluence: no gaps in monolayer (gaps cause artifactual barrier loss). If targeting survival genes or junctional proteins, some disruption expected; document and include in interpretation.

Optimization strategies for endothelial cell applications

Troubleshooting

TEER drops in non-targeting control ASO

• Verify confluence before ASO treatment: phase-contrast microscopy should show tight cobblestone morphology with no gaps
• Measure baseline TEER before ASO and read every later value against it
• Test ASO stock for endotoxin (<0.1 EU/mL required for endothelial cells)
• Prepare fresh ASO stock, use sterile technique
• Verify CO₂ incubator calibration (5% CO₂), use HEPES-buffered medium if CO₂ unstable
• Use early-passage HUVECs (P2-P6), verify VE-cadherin expression by flow cytometry before experiments

Low knockdown efficiency (<50%)

• Increase ASO concentration within 5-20 μM and re-test
• Test positive control target (GAPDH, ACTB) to verify ASO activity
• Use fresh ASO stock, store at -20°C in single-use aliquots
• Verify cell health: viability >95%, cobblestone morphology, passage <7
• Design alternative ASO targeting different region of same mRNA
• Extend incubation to 96h for targets with very long half-life

Cell retraction or gap formation during treatment

• If targeting VE-cadherin, claudin-5, ZO-1, or other junctional proteins: retraction expected (document as functional validation)
• If targeting non-junctional genes: reduce ASO within 5-20 μM, test if retraction resolves
• Include untreated and non-targeting control; if both show normal morphology but experimental ASO causes retraction, indicates target-specific effect
• Test for endotoxin, use fresh ASO stock
• Use early-passage cells, verify starting monolayer quality

Tube formation assay shows no difference despite knockdown

• Verify target gene knockdown by qRT-PCR and Western blot
• Positive control: knock down VEGFR2 or VEGFA; both should drastically reduce tube formation (50-80% reduction)
• Ensure tube formation assay performed at 72h post-ASO, not earlier
• Use growth factor-reduced basement membrane matrix (standardized, low VEGF/FGF2 background)
• Consider pathway redundancy; may require dual knockdown (e.g., VEGFR2 + FGFR1)
• For Notch pathway genes (DLL4, NOTCH1), expect altered tip-stalk balance (hypersprouting with DLL4 knockdown), not complete block of tube formation

High baseline permeability (cannot detect knockdown-induced increase)

• Verify confluence by microscopy before permeability assay
• Measure TEER immediately before adding FITC-dextran and confirm the monolayer is at its own plateau
• Use fresh permeable inserts, avoid touching membrane with pipette (creates holes)
• Equilibrate medium volumes in apical and basolateral chambers (prevent hydrostatic pressure driving convective flow)
• Reduce FITC-dextran concentration (use 0.5-1 mg/mL, not 5-10 mg/mL)
• Optimize timepoint: measure flux at 1h, 2h, 4h; select timepoint with linear flux in control condition

Quantitative RT-PCR (qRT-PCR)

Western blot

Immunofluorescence for junction protein localization

Transendothelial electrical resistance (TEER) measurement

Paracellular permeability assays (FITC-dextran flux)

Tube formation assay on basement membrane matrix

Spheroid sprouting assay

Scratch wound migration assay

Flow cytometry for surface marker knockdown

Leukocyte adhesion assay

Critical controls for endothelial cell validation

• Untreated endothelial cells
  Purpose: Baseline for morphology, TEER, permeability, tube formation, and junction protein localization
  Culture identically but without ASO. Critical for verifying AUMsilence sdASO itself does not disrupt barrier function or angiogenic capacity. Compare all measurements to untreated cells.
• Non-targeting control ASO
  Purpose: Control for non-specific ASO effects on endothelial function
  Use AUM non-targeting control at 10 μM (match experimental ASO concentration). Measure TEER, permeability, VE-cadherin localization, tube formation, ICAM-1/VCAM-1 expression; all should match untreated exactly. If non-targeting ASO alters any parameter, suggests off-target effect or endotoxin contamination.
• Positive control for barrier disruption
  Purpose: Validate that barrier assays detect endothelial dysfunction
  Thrombin (1 U/mL, 10 min): rapid VE-cadherin disassembly, TEER drop 50-80%, increased permeability (positive control for barrier breakdown). VEGF (50 ng/mL, 30 min): increased permeability, moderate TEER drop (vascular leak control). TNF-α (10 ng/mL, 4-6h): ICAM-1/VCAM-1 upregulation (inflammatory activation control).
• Junction integrity validation by immunofluorescence
  Purpose: Ensure baseline junctions intact before and during ASO treatment
  Immunofluorescence for VE-cadherin and ZO-1 at Day 0 (before ASO) and Day 3 (after ASO in non-targeting control). Both should show continuous linear staining at cell-cell borders. Discontinuous or diffuse staining indicates junction disruption (experimental problem, not target-specific effect).
• Angiogenesis-competent cell verification
  Purpose: Ensure cells retain angiogenic capacity before knockdown experiments
  Test tube formation in non-targeting control and untreated cells (should form extensive networks). Test VEGF responsiveness: tube formation ± VEGF (50 ng/mL); VEGF should enhance tubes. If control cells fail to form tubes, indicates poor cell health, excessive passage number, or inadequate basement membrane matrix quality.
• Viability and confluence assessment
  Purpose: Ensure ASO treatment does not cause cytotoxicity or monolayer gaps
  At 24h, 48h, 72h after treatment: (1) Viability: trypan blue or viability/cytotoxicity dual staining, (2) Morphology: cobblestone morphology maintained, (3) Confluence: no gaps in monolayer (gaps cause artifactual barrier loss). If targeting survival genes (VEGFR2 at high efficiency) or junctional proteins, some disruption expected; document and include in interpretation.

Best practices

• Use early-passage primary endothelial cells (HUVECs P2-P6, brain ECs P3-P8) to avoid senescence and phenotype drift
• Validate knockdown at both mRNA (qRT-PCR, 48h after treatment) and protein (Western blot, immunofluorescence, or flow cytometry, 72h) levels
• For barrier studies, measure both TEER (quantitative, real-time) and permeability assays (FITC-dextran flux); complementary readouts
• Include immunofluorescence for junction proteins (VE-cadherin, claudin-5, ZO-1) to visualize spatial localization and verify junction integrity in controls
• For angiogenesis assays, use multiple readouts: tube formation (2D, rapid), sprouting (3D, physiological), migration (scratch wound, simple)
• Measure viability, morphology, and confluence at each timepoint; report in publications to demonstrate preserved cell health
• For functional assays (tube formation, permeability, leukocyte adhesion), verify knockdown in same cells used for functional readout
• Use biological triplicates (n=3 independent experiments) for primary cells; technical triplicates within each experiment for reproducibility
• For BBB studies, verify astrocyte co-culture enhances the barrier; compare permeable insert with vs. without astrocytes in bottom chamber
• Include appropriate statistical tests: t-test for two groups, ANOVA for multiple groups, p<0.05 threshold. For dose-response, use linear regression.